Alterity Therapeutics (ATHE) Cash & Equivalents (2009 - 2025)

Alterity Therapeutics' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $32.3 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 988.88% year-over-year to $32.3 million; the TTM figure through Dec 2025 stood at $32.3 million (up 988.88% YoY), while the FY2025 annual figure was $21.2 million, up 16702.03% from the prior year.
• Cash & Equivalents was $32.3 million for Q4 2025 at Alterity Therapeutics, up from $21.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $32.3 million in Q4 2025 to a low of $3.0 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $17.4 million across 5 years, with a median of $18.9 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 63.01% in 2024, then soared 988.88% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $27.0 million in 2021, then sank by 38.24% to $16.6 million in 2022, then slumped by 51.82% to $8.0 million in 2023, then sank by 63.01% to $3.0 million in 2024, then jumped by 988.88% to $32.3 million in 2025.
• The last three Cash & Equivalents figures came in at $32.3 million (Q4 2025), $21.2 million (Q2 2025), and $3.0 million (Q4 2024), per Business Quant data.